Shin Nippon Biomedical Laboratories, Ltd.
Notice Regarding Revisions to Consolidated Earnings Forecast for the Second Quarter of the Fiscal Year Ending March 2027
Revised the consolidated earnings forecast for the second quarter of the fiscal year ending March 2027. Net sales revised up from 16,596 million yen to 17,154 million yen (+558 million yen, +3.4%), operating income revised up from 463 million yen to 1,240 million yen (+777 million yen, +167.8%), ordinary income revised up from 1,948 million yen to 2,988 million yen (+1,040 million yen, +53.4%), and net income attributable to owners of the parent revised up from 1,167 million yen to 1,917 million yen (+750 million yen, +64.3%). The principal drivers are the steady progress of the CRO business, a delay in recognizing expenses in the TR business in the second half, and foreign exchange gains (172 million yen).
Key Figures
- Net sales: 16,596百万円→17,154百万円（+3.4%）
- Operating income: 463百万円→1,240百万円（+167.8%）
- Ordinary income: 1,948百万円→2,988百万円（+53.4%）
AI要約
Overview of the earnings revision
We revised the consolidated earnings forecast for the second quarter (interim period) of the fiscal year ending March 2027, as announced on May 11, 2026, for the period from April 1, 2026 to September 30, 2026. Net sales are expected to exceed the previous forecast owing to the steady progress of the CRO business, and operating income, ordinary income, and net income are all expected to rise significantly. Additionally, foreign exchange gains recorded in the first quarter contributed to the revision.
Outlook and key factors
The main factors behind the revision are the stable growth of the CRO business, expected delays in expense recognition in the TR business in the second half, and foreign exchange gains of 172 million yen in the first quarter. The foreign exchange assumption for the fiscal year ending March 2027 remains at 150.00 yen/USD. Actual results may fluctuate depending on future exchange movements and progress across each business.
NIPPON STEEL SCIENCE CORPORATION
Company overview · Stock price · Financial data · All IR
